Adial Pharmaceuticals, Inc. Proceeds from Debt, Net of Issuance Costs
Adial Pharmaceuticals, Inc. (ADIL) reported Proceeds from Debt, Net of Issuance Costs of $5.30 million for the 1-month period ending 2025-06-30, per its 10-Q filed 2025-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2025-08-13
- Adial Pharmaceuticals, Inc. proceeds from debt, net of issuance costs for fiscal 2023 was $9.12M.
| Period end | Proceeds from Debt, Net of Issuance Costs | Proceeds from Debt, Net of Issuance Costs 0 month | Proceeds from Debt, Net of Issuance Costs 1 month | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-06-30 | $5.30M 10-Q · filed 2025-08-13 | |||
| 2025-05-31 | $5.30M 10-Q · filed 2025-08-13 | |||
| 2024-07-24 | $3.66M 10-Q · filed 2024-08-13 | |||
| 2024-03-01 | $3.10M 10-Q · filed 2024-11-13 | |||
| 2023-12-31 | $9.12M 10-K · filed 2024-04-01 | |||
| 2023-10-31 | $3.40M 10-K · filed 2024-04-01 | |||
| 2022-02-10 | $9.12M 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |